Bionexus Gene Lab

What Bionexus Gene Lab does

BioNexus Gene Lab Corporation (NASDAQ: BGLC) is a Wyoming-incorporated diagnostics parent operating through its Malaysian subsidiary MRNA Scientific Sdn Bhd, with US corporate offices in Sheridan, Wyoming, and operational headquarters and laboratory facilities in Kuala Lumpur and Penang, Malaysia. The company's core offering is Blood-Based Genomic Screening (BGS), a non-invasive blood test that analyzes circulating RNA to assess individual risk for eight common cancers, two inflammatory diseases, and osteoarthritis before symptoms appear, derived from original work by the late Prof. Emeritus Dato Dr. Liew Choong-Chin. In December 2025 BioNexus expanded into oncology monitoring by acquiring a 15% equity stake in Singapore-based Fidelion Diagnostics and securing exclusive perpetual ASEAN rights to the VitaGuard MRD liquid biopsy platform, which uses proprietary cfDNA recovery and high-frequency sequencing workflows to target per-patient MRD monitoring costs below $300 versus the prevailing $3,000+ standard.

Revenue mechanics blend direct-to-patient BGS testing through Malaysian lab offices, chemical raw materials distribution through the Chemrex Corporation Sdn Bhd subsidiary (serving research institutions and laboratories in Southeast Asia), licensing and royalty arrangements tied to the VitaGuard platform (including a $2M perpetual license fee payable over 24 months), and equity exposure to Fidelion Diagnostics. The go-to-market combines its own clinical lab network (Lifecare Medical Centre in Kuala Lumpur, University Science Malaysia in Penang) with Fidelion as the exclusive international commercialization vehicle and enterprise field sales targeting healthcare systems and clinical laboratories across ASEAN. Customer segments span individual patients seeking cancer screening, healthcare providers and oncology centers requiring affordable MRD monitoring, and research buyers of chemical reagents.

The company completed a $5M NASDAQ uplisting in July 2023 at $4 per share, then layered in a $100M SEC shelf with a $20M ATM program (November 2025) and a $500M equity purchase agreement with ARC Group International (December 2025) to fund expansion. Despite an aggressive partnership and capital strategy, market capitalization stood at approximately $5.15M with a 45% year-to-date stock decline as of March 2026, no disclosed revenue, and the VitaGuard MRD platform only formally entering its 2026 deployment phase in January 2026.

Name

Bionexus Gene Lab

Legal name

BioNexus Gene Lab Corporation

Website

https://bionexusgenelab.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

BioNexus Gene Lab Corp (NASDAQ: BGLC) provides RNA-based blood genomic screening for early detection of eight common cancers and inflammatory diseases, and exclusively distributes the VitaGuard MRD liquid biopsy platform across Southeast Asia via its Malaysian operations.

Ownership category

akta.pro rank

Product category

Genomic Diagnostics and Liquid Biopsy

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

akta.pro secondary industries

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Blood-based genomic screening
• Liquid biopsy diagnostics
• RNA-based disease detection
• Minimal residual disease testing
• Early cancer screening

Headquarters

HQ city

Kuala Lumpur

HQ country

Malaysia

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

1. Precision Oncology Diagnostics: Revenue from diagnostic testing services including the VitaGuard MRD platform for minimal residual disease monitoring across Southeast Asia. Commercialization through Fidelion Diagnostics with exclusive rights for ASEAN markets.
2. Chemical Raw Materials Sales: Subsidiary Chemrex sells chemical raw materials in Southeast Asia including Malaysia, providing recurring revenue from chemical product distribution.
3. Licensing and Royalties: Perpetual, royalty-free rights to develop and sell VitaGuard-based products in Southeast Asia in exchange for a license fee and reagent commitments.
4. Strategic Investment Returns: 15% equity stake in Fidelion Diagnostics provides exposure to global AI-oncology platform and potential capital returns.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

BioNexus Gene Lab applies less-invasive blood-based dynamic genome screening (BGS) that analyzes changes in RNA to predict certain predisposed diseases before symptoms appear. Its core offering includes a BGS blood test assessing risk for 8 common cancers, 2 inflammatory diseases, and osteoarthritis, plus the VitaGuard MRD Platform, an AI-enabled liquid biopsy for minimal residual disease monitoring targeting costs below $3,000 per patient.

Differentiator

Problem solved

Functional benefit

Brands

• VitaGuard MRD Platform: AI-enabled minimal residual disease (MRD) liquid biopsy platform for cancer monitoring, developed through partnership with Fidelion Diagnostics and Tongshu Gene
• Blood-Based Genomic Screening (BGS)

Products and services

• Blood-Based Genomic Screening (BGS) A less-invasive blood test that uses circulating RNA to assess an individual's current risk for a panel of 8 common cancers, 2 inflammatory diseases, and osteoarthritis, enabling early disease detection before symptoms appear.
• VitaGuard MRD Platform AI-enabled liquid biopsy platform for minimal residual disease (MRD) monitoring using proprietary cfDNA recovery and high-frequency sequencing workflows to establish routine longitudinal cancer monitoring at cost profiles below the $3,000 barrier.
• Chemical Raw Materials Distribution (Chemrex) Chemical raw materials distribution in Southeast Asia including Malaysia, provided through Chemrex Corporation Sdn. Bhd. subsidiary to research institutions and laboratories.

Quantifiable outcome

• 90% reduction in per-patient MRD monitoring costs from over US$3,000 to under US$300
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Malaysia-China Precision Healthcare CorridorcoreStrategic or Co-development Partner · 21 May 2026BioNexus participates in the 2026 China–Malaysia Economic Cooperation Outlook Forum advocating for a Malaysia–China precision healthcare corridor that moves beyond traditional trade into co-development, clinical validation, and commercialization. The model pairs China-origin biotechnology innovation with Malaysia-based ASEAN execution capabilities.
• Tongshu GenecoreTechnology or Integration · 28 January 2026Patent Support Agreement signed with Tongshu Gene for the VitaGuard MRD platform. Tongshu Gene Biotechnology Co., Limited serves as the partner for manufacturing and R&D of the technology originally developed in China.
• Fidelion Diagnostics Pte. Ltd.coreStrategic or Co-development Partner · 3 December 2025BioNexus acquired 15% equity stake in Fidelion Diagnostics through non-cash share swap, with Fidelion acquiring approximately 16.6% of BGLC's stock. BGLC secured exclusive, perpetual rights to manufacture, market, and distribute the VitaGuard AI-enabled liquid biopsy platform across all ASEAN markets. The transaction establishes a dual-asset model positioning BGLC as both a commercial operator and strategic shareholder.
• BirchBioMed Inc.minorStrategic or Co-development Partner · 20 October 2025Non-binding strategic partnership term sheet with BirchBioMed Inc., a Canadian biopharmaceutical company, to collaborate on developing Birch's FS2 topical platform in Southeast Asia. The partnership involves a USD 10 million financing round, strategic investment, and collaboration to accelerate commercialization in Malaysia and Singapore.

Scale indicators9 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Natera: US-based leader in cell-free DNA testing with its Signatera MRD platform, the established benchmark BioNexus's VitaGuard aims to undercut on price across ASEAN. Both companies offer tumor-informed liquid biopsy for longitudinal cancer monitoring.
• Guardant Health: Specialized liquid biopsy company with the Guardant Reveal MRD test and broader oncology blood screening portfolio. Operates at the same price-point range BioNexus is targeting to disrupt, and shares the same blood-based cfDNA/RNA diagnostic model.

Regional players

• MiRXES: Singapore-headquartered RNA-based early cancer detection company with direct operational overlap in the ASEAN market BioNexus is targeting. Also a NASDAQ-listed Asia-focused diagnostics company built on circulating RNA biomarkers.
• Lucence Diagnostics: Singapore-based liquid biopsy company offering cancer screening and treatment selection tests, including ultrasensitive ctDNA assays. Direct geographic and product overlap with BioNexus's VitaGuard MRD positioning in Southeast Asia.
• Burning Rock Biotech: China-based cancer genomics company with MRD and liquid biopsy offerings, providing the closest analogue to BGLC's China-originated VitaGuard technology. Shares the cross-border commercialization model and ASEAN expansion thesis.

Broad incumbents

• Exact Sciences: Large-cap multi-cancer screening company (Cologuard, Oncotype DX) that defines the clinical and commercial bar for blood-based cancer diagnostics. Comparable to BioNexus on the multi-cancer blood screening use case via BGS.
• NeoGenomics: US-listed oncology-focused clinical laboratory services company with MRD and liquid biopsy capabilities. Comparable operating model to BioNexus as a public-lab-services and oncology-diagnostics platform.

Emerging players

• Mainz Biomed: Early-to-mid stage molecular diagnostics company focused on blood-based cancer screening, with similar disruptive-cost positioning to BioNexus VitaGuard. Comparable as a smaller-cap emerging cancer screening peer.
• Personalis: Cancer genomics company with tumor-informed MRD (NeXT Personal) and immuno-oncology offerings. Comparable in product overlap (MRD liquid biopsy) and stage profile to BioNexus's VitaGuard commercialization.
• Novogene: China-headquartered genomics services provider with sequencing and bioinformatics capabilities. Provides regional comparability for the Chinese R&D and sequencing infrastructure that underpins the VitaGuard platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bglc

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bionexus Gene Lab